Therapy Acceleration Program® (TAP): filling a “gap” in our research programs

Time frame from a discovery in biology to a therapy for patients: 7 – 10 years

Discovery \[\rightarrow\] Development \[\rightarrow\] Approval

CDP \[\rightarrow\] TRP

SCOR

New Therapies!

Academic Grants Program

TAP program!

someday is today
Therapy Acceleration Program® (TAP)

More Therapies to More Patients, Faster

Biotechnology Accelerator
Funding is project specific, tranched, current high $12.5M

Academic Concierge
Funding is project specific, tranched, current high $6M

Clinical Trials Program
Funding is project specific, tranched, current high $>1M

Special Initiatives
Funding is project specific, tranched, current high $>8M

47 collaborations and supported projects; ~ $78 million invested
Blood Cancer Research Partnership (BCRP)

- **Goal:** Establish a network to accelerate the development of and expand access to well-designed and innovative clinical trials for blood cancer patients being treated at community sites.

- **Why did we establish BCRP:**
  - Over 80% of patients with cancer in the United States are being treated in the community.
  - Only 5% of patients with hematological malignancies participate in clinical trials.

- **Partners:**
  - A leading academic cancer institute (Dana-Farber Cancer Institute, DFCI).
  - A premier foundation (The Leukemia and Lymphoma Society).
  - A select group of community oncologists - 11 sites across the continental US.
BCRP Operation and Outcome

- LLS provides infrastructure support to DFCI, no funding for the trials
- Mutually agreed Milestones and Deliverables
- Trials need the approval of all partners
- Biweekly enrollment update; monthly meeting; quarterly formal progress review; annual BCRP investigator summit

18-month Outcome:
- Three trials open at BCRP sites
- Four trials open soon
- Four trials in development
- Presentation at scientific conferences
- **Addition of BCRP sites has increased screening and enrollment when compared to DFCI alone thus shortened the trials**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Enrollment Rate Increase</th>
<th>Enrollment Time Decrease (est.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCRP-001</td>
<td>235% in Part B</td>
<td>1 year for Part B</td>
</tr>
<tr>
<td>BCRP-002</td>
<td>54%</td>
<td>3 months</td>
</tr>
<tr>
<td>BCRP-003</td>
<td>115%</td>
<td>6 months</td>
</tr>
</tbody>
</table>